Development of measures of polyneuropathy impairment in hATTR amyloidosis

From NIS to mNIS + 7

P. James B. Dyck, A. González-Duarte, L. Obici, M. Polydefkis, J. F. Wiesman, I. Antonino, W. J. Litchy, Peter J. Dyck

Research output: Contribution to journalReview article

Abstract

Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.

Original languageEnglish
Article number116424
JournalJournal of the Neurological Sciences
Volume405
DOIs
Publication statusPublished - Oct 15 2019

Fingerprint

Polyneuropathies
Amyloidosis
Clinical Trials
Stretch Reflex
Prealbumin
Muscle Weakness
Point Mutation
Disease Progression
Lower Extremity
Physicians
Muscles
Genes

Keywords

  • Hereditary transthyretin-mediated amyloidosis
  • Modified neuropathy impairment score+7
  • Neuropathy impairment score
  • Polyneuropathy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Dyck, P. J. B., González-Duarte, A., Obici, L., Polydefkis, M., Wiesman, J. F., Antonino, I., ... Dyck, P. J. (2019). Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. Journal of the Neurological Sciences, 405, [116424]. https://doi.org/10.1016/j.jns.2019.116424

Development of measures of polyneuropathy impairment in hATTR amyloidosis : From NIS to mNIS + 7. / Dyck, P. James B.; González-Duarte, A.; Obici, L.; Polydefkis, M.; Wiesman, J. F.; Antonino, I.; Litchy, W. J.; Dyck, Peter J.

In: Journal of the Neurological Sciences, Vol. 405, 116424, 15.10.2019.

Research output: Contribution to journalReview article

Dyck, PJB, González-Duarte, A, Obici, L, Polydefkis, M, Wiesman, JF, Antonino, I, Litchy, WJ & Dyck, PJ 2019, 'Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7', Journal of the Neurological Sciences, vol. 405, 116424. https://doi.org/10.1016/j.jns.2019.116424
Dyck, P. James B. ; González-Duarte, A. ; Obici, L. ; Polydefkis, M. ; Wiesman, J. F. ; Antonino, I. ; Litchy, W. J. ; Dyck, Peter J. / Development of measures of polyneuropathy impairment in hATTR amyloidosis : From NIS to mNIS + 7. In: Journal of the Neurological Sciences. 2019 ; Vol. 405.
@article{4f178ee824de4a56a7d19fb3cc81686b,
title = "Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7",
abstract = "Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.",
keywords = "Hereditary transthyretin-mediated amyloidosis, Modified neuropathy impairment score+7, Neuropathy impairment score, Polyneuropathy",
author = "Dyck, {P. James B.} and A. Gonz{\'a}lez-Duarte and L. Obici and M. Polydefkis and Wiesman, {J. F.} and I. Antonino and Litchy, {W. J.} and Dyck, {Peter J.}",
year = "2019",
month = "10",
day = "15",
doi = "10.1016/j.jns.2019.116424",
language = "English",
volume = "405",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Development of measures of polyneuropathy impairment in hATTR amyloidosis

T2 - From NIS to mNIS + 7

AU - Dyck, P. James B.

AU - González-Duarte, A.

AU - Obici, L.

AU - Polydefkis, M.

AU - Wiesman, J. F.

AU - Antonino, I.

AU - Litchy, W. J.

AU - Dyck, Peter J.

PY - 2019/10/15

Y1 - 2019/10/15

N2 - Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.

AB - Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.

KW - Hereditary transthyretin-mediated amyloidosis

KW - Modified neuropathy impairment score+7

KW - Neuropathy impairment score

KW - Polyneuropathy

UR - http://www.scopus.com/inward/record.url?scp=85070893314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070893314&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.116424

DO - 10.1016/j.jns.2019.116424

M3 - Review article

VL - 405

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

M1 - 116424

ER -